N-(6,7-dichloro-2,3-dimethoxyquinoxalin-5-yl)ethanesulphonamide | 178907-21-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-(6,7-dichloro-2,3-dimethoxyquinoxalin-5-yl)ethanesulphonamide
• 英文别名: N-(6,7-dichloro-2,3-dimethoxyquinoxalin-5-yl)ethanesulfonamide
• CAS: 178907-21-6
• 化学式: C₁₂H₁₃Cl₂N₃O₄S
• 分子量: 366.225
• InChiKey: JDFQQIGALPNHEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  98.8
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-(6,7-dichloro-2,3-dimethoxyquinoxalin-5-yl)ethanesulphonamide 在 盐酸 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 10.0h， 生成 N-(6,7-dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-(3,3,3-trifluoropropyl)ethanesulfonamide
  参考文献：
  名称：

  N-(6,7-Dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-d-aspartate receptor antagonists for the treatment of pain

  摘要：

  It has been hypothesized that peripherally restricted NMDA receptor antagonists may be effective analgesics for osteoarthritis pain. A class of novel quinoxalinedione atropisomers, first discovered for an NMDA receptor antagonist program for the treatment of stroke, was evaluated and further optimized with the goal of finding peripherally restricted NMDA receptor antagonists. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.083
• 作为产物：
  描述：

  6,7-二氯-2,3-二甲氧基-5-喹喔啉胺 在 吡啶 、 sodium hydroxide 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成 N-(6,7-dichloro-2,3-dimethoxyquinoxalin-5-yl)ethanesulphonamide
  参考文献：
  名称：

  N-(6,7-Dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-d-aspartate receptor antagonists for the treatment of pain

  摘要：

  It has been hypothesized that peripherally restricted NMDA receptor antagonists may be effective analgesics for osteoarthritis pain. A class of novel quinoxalinedione atropisomers, first discovered for an NMDA receptor antagonist program for the treatment of stroke, was evaluated and further optimized with the goal of finding peripherally restricted NMDA receptor antagonists. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.083

文献信息

• Quinoxaline derivatives useful in therapy
  申请人：Pfizer Inc.

  公开号：US05852016A1

  公开（公告）日：1998-12-22

  Compounds of formula (I), wherein A represents N or CH; R.sup.1 and R.sup.2 independently represent C.sup.1-4 alkyl, halo or CF.sub.3 ; R.sup.3 represents C.sub.1-4 alkyl (optionally substituted), C.sub.3-7 cycloalkyl, CF.sub.3 or aryl; R.sup.4 represents H, C.sub.3-7 cycloalkyl or C.sub.1-6 alkyl (optionally substituted); and their pharmaceutically acceptable derivatives; are useful in the treatment of, inter alia, neurodogenerative disorders. ##STR1##

  式（I）的化合物，其中A代表N或CH；R.sup.1和R.sup.2分别代表C.sup.1-4烷基，卤素或CF.sub.3；R.sup.3代表C.sub.1-4烷基（可选取代），C.sub.3-7环烷基，CF.sub.3或芳基；R.sup.4代表H，C.sub.3-7环烷基或C.sub.1-6烷基（可选取代）；以及它们的药学上可接受的衍生物；在治疗神经退行性疾病等方面是有用的。
• QUINOXALINE DERIVATIVES USEFUL IN THERAPY
  申请人：Pfizer Limited

  公开号：EP0783495B1

  公开（公告）日：2002-02-27
• US5852016A
  申请人：——

  公开号：US5852016A

  公开（公告）日：1998-12-22
• [EN] QUINOXALINE DERIVATIVES USEFUL IN THERAPY<br/>[FR] DERIVES DE QUINOXALINE UTILES EN THERAPIE
  申请人：PFIZER LIMITED

  公开号：WO1996009295A1

  公开（公告）日：1996-03-28

  (EN) Compounds of formula (I), wherein A represents N or CH; R1 and R2 independently represent C1-4 alkyl, halo or CF3; R3 represents C1-4 alkyl (optionally substituted), C3-7 cycloalkyl, CF3 or aryl; and R4 represents H, C3-7 cycloalkyl or C1-6 alkyl (optionally substituted); and their pharmaceutically acceptable derivatives; are useful in the treatment of, $i(inter alia), neurodogenerative disorders.(FR) Composés de la formule (I), ainsi que leurs dérivés acceptables sur le plan pharmacologique, dans laquelle A représente N ou CH; R1 et R2 représentent indépendamment alkyle C1-4, halo ou CF3; R3 représente alkyle C1-4 (éventuellement substitué), cycloalkyle C3-7, CF3 ou aryle; et R4 représente H, cycloalkyle C3-7 ou alkyle C1-6 (éventuellement substitué). Ces composés sont utiles dans le traitement, entre autres, des affections dégénératives neuronales.
• N-(6,7-Dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-d-aspartate receptor antagonists for the treatment of pain
  作者：Christopher Deur、Arun K. Agrawal、Heidi Baum、John Booth、Susan Bove、Joan Brieland、Amy Bunker、Cleo Connolly、Joseph Cornicelli、JoAnn Dumin、Barry Finzel、Xinmin Gan、Sheila Guppy、Gregg Kamilar、Kenneth Kilgore、Pil Lee、Cho-Ming Loi、Zhen Lou、Mark Morris、Laurence Philippe、Sally Przybranowski、Frank Riley、Brian Samas、Brian Sanchez、Haile Tecle、Ziqiang Wang、Kathryn Welch、Michael Wilson、Karen Yates

  DOI：10.1016/j.bmcl.2007.05.083

  日期：2007.8

  It has been hypothesized that peripherally restricted NMDA receptor antagonists may be effective analgesics for osteoarthritis pain. A class of novel quinoxalinedione atropisomers, first discovered for an NMDA receptor antagonist program for the treatment of stroke, was evaluated and further optimized with the goal of finding peripherally restricted NMDA receptor antagonists. (c) 2007 Elsevier Ltd. All rights reserved.